

## TN16 Long-Term Investigative Follow Up in TrialNet Eligibility Form

29JUL2015 Version 1.7 Page 1 of 1

Site Number: Date of Visit: Person Completing Form: Participant ID: Participant Letters:

O TN01 Natural History 1. Select the TrialNet Study in which the subject last participated \* (Pathway to Prevention) O TN05 Anti-CD20 (Rituximab) O TN06 NIP Pilot Diabetes Study O TN07 Oral Insulin O TN08 GAD New Onset O TN09 CTLA-4Ig (Abatacept) O TN10 Anti-CD3 (Teplizumab) O TN12 Metabolic Outcomes O TN14 Anti-IL1 (Canakinumab) O TN18 Abatacept Prevention O TN19 ATG-GCSF New Onset 2. Subject or Authorized Legal Representative has signed written informed OY ON consent/assent, as applicable. \* If yes, date consent/assent was obtained: \* Is subject willing to allow TrialNet to put any remaining blood samples in the OY ON NIDDK repository? \* 3. Date of Diagnosis \*